Integrative analysis of Alzheimer's disease molecular networks with circadian regulators for prioritization of drug repurposing candidates.

IF 3.4 3区 医学 Q2 NEUROSCIENCES
Alexandros Zantis, Elisa Uliassi, Chiara Pallara, Xinzhong Li
{"title":"Integrative analysis of Alzheimer's disease molecular networks with circadian regulators for prioritization of drug repurposing candidates.","authors":"Alexandros Zantis, Elisa Uliassi, Chiara Pallara, Xinzhong Li","doi":"10.1177/13872877261497407","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundAlzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by complex molecular mechanisms. Growing evidence indicates that circadian rhythm disruption contributes to disease progression and interacts with pathogenic pathways. Although multi-omics resources, compound perturbation profiles, and pharmacological bioactivity data are increasingly available, their integrative use for drug repurposing prioritization in AD, particularly with explicit consideration of circadian rhythm, remains limited.ObjectiveThis study aimed to prioritize drug repurposing candidates for AD, by integrating heterogeneous biological and pharmacological data.MethodsWe applied an integrative, systems-level computational analysis to prioritize drug repurposing and repositioning candidates for AD by combining network-based gene prioritization, functional transcriptomic similarity analysis, and target-level bioactivity prediction. Disease-associated molecular modules were identified within the human protein-protein interaction network, with circadian rhythm regulators incorporated as an additional disease relevant biological context. These modules were represented using functional gene embeddings to rank compound perturbation signatures. Candidate compounds were subsequently refined through ligand-based bioactivity prediction across AD associated targets to support polypharmacological prioritization.ResultsThe analysis prioritized compounds supported by convergent network-level disease relevance, transcriptomic similarity, and predicted target engagement. Several drugs previously investigated in dementia-related clinical trials were recovered. Novel repositioning candidates, including PF-562271, MGCD-265, and BMS-777607, were identified, converging on focal adhesion kinase (FAK), PI3K-AKT, and receptor tyrosine kinase (RTK) signaling pathways enriched in AD-associated genes and implicated in circadian regulation and neuroinflammation.ConclusionsThis integrative analysis identifies mechanistically coherent repurposing candidates, associated with circadian and inflammatory pathways, supporting systems-based strategies for therapeutic prioritization in complex neurodegenerative diseases.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261497407"},"PeriodicalIF":3.4000,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877261497407","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundAlzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by complex molecular mechanisms. Growing evidence indicates that circadian rhythm disruption contributes to disease progression and interacts with pathogenic pathways. Although multi-omics resources, compound perturbation profiles, and pharmacological bioactivity data are increasingly available, their integrative use for drug repurposing prioritization in AD, particularly with explicit consideration of circadian rhythm, remains limited.ObjectiveThis study aimed to prioritize drug repurposing candidates for AD, by integrating heterogeneous biological and pharmacological data.MethodsWe applied an integrative, systems-level computational analysis to prioritize drug repurposing and repositioning candidates for AD by combining network-based gene prioritization, functional transcriptomic similarity analysis, and target-level bioactivity prediction. Disease-associated molecular modules were identified within the human protein-protein interaction network, with circadian rhythm regulators incorporated as an additional disease relevant biological context. These modules were represented using functional gene embeddings to rank compound perturbation signatures. Candidate compounds were subsequently refined through ligand-based bioactivity prediction across AD associated targets to support polypharmacological prioritization.ResultsThe analysis prioritized compounds supported by convergent network-level disease relevance, transcriptomic similarity, and predicted target engagement. Several drugs previously investigated in dementia-related clinical trials were recovered. Novel repositioning candidates, including PF-562271, MGCD-265, and BMS-777607, were identified, converging on focal adhesion kinase (FAK), PI3K-AKT, and receptor tyrosine kinase (RTK) signaling pathways enriched in AD-associated genes and implicated in circadian regulation and neuroinflammation.ConclusionsThis integrative analysis identifies mechanistically coherent repurposing candidates, associated with circadian and inflammatory pathways, supporting systems-based strategies for therapeutic prioritization in complex neurodegenerative diseases.

阿尔茨海默病分子网络与昼夜节律调节因子的综合分析,以确定药物再利用候选药物的优先级。
阿尔茨海默病(AD)是一种多因素神经退行性疾病,具有复杂的分子机制。越来越多的证据表明,昼夜节律紊乱有助于疾病进展,并与致病途径相互作用。尽管多组学资源、化合物扰动谱和药理学生物活性数据越来越多,但它们在阿尔茨海默病药物再利用优先排序中的综合应用,特别是明确考虑昼夜节律的应用,仍然有限。目的本研究旨在通过整合异质生物学和药理学数据,优选AD的候选药物。方法采用综合的系统级计算分析方法,结合基于网络的基因优先排序、功能转录组相似性分析和靶标水平生物活性预测,对阿尔茨海默病的药物再利用和重新定位候选药物进行优先排序。在人类蛋白质-蛋白质相互作用网络中确定了与疾病相关的分子模块,并将昼夜节律调节因子作为额外的疾病相关生物学背景。这些模块使用功能基因嵌入来对复合扰动特征进行排序。候选化合物随后通过基于配体的AD相关靶点生物活性预测进行细化,以支持多药理学优先排序。结果该分析优先考虑了具有趋同网络水平疾病相关性、转录组相似性和预测靶标参与的化合物。以前在痴呆症相关临床试验中研究的几种药物被恢复。新的重新定位候选物,包括PF-562271、MGCD-265和BMS-777607,聚集在ad相关基因富集的局灶黏着激酶(FAK)、PI3K-AKT和受体酪氨酸激酶(RTK)信号通路上,参与昼夜调节和神经炎症。结论:该综合分析确定了与昼夜节律和炎症途径相关的机制一致的重新定位候选药物,支持基于系统的复杂神经退行性疾病治疗优先级策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Alzheimer's Disease
Journal of Alzheimer's Disease 医学-神经科学
CiteScore
6.40
自引率
7.50%
发文量
1327
审稿时长
2 months
期刊介绍: The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书